Treatment of seborrheic dermatitis: a comprehensive review

References

• Borda LJ, Wikramanayake TC. Seborrheic dermatitis and dandruff: a comprehensive review. J Clin Investigat Dermatol. 2015;3:1–10.
   Google Scholar
• Schwartz JR, Messenger AG, Tosti A, et al. A comprehensive pathophysiology of dandruff and seborrheic dermatitis – towards a more precise definition of scalp health. Acta Derm Venereol. 2013;93:131–137.
   PubMed Web of Science ®Google Scholar
• Dessinioti C, Katsambas A. Seborrheic dermatitis: etiology, risk factors, and treatments: facts and controversies. Clin Dermatol. 2013;31:343–351.
   PubMed Web of Science ®Google Scholar
• Sampaio AL, Mameri AC, Vargas TJ, et al. Seborrheic dermatitis. An Bras Dermatol. 2011;86:1061–1071.
   PubMed Web of Science ®Google Scholar
• Bukvic Mokos Z, Kralj M, Basta-Juzbasic A, et al. Seborrheic dermatitis: an update. Acta Dermatovenerol Croat. 2012;20:98–104.
   PubMed Web of Science ®Google Scholar
• Buechner SA. Multicenter, double-blind, parallel group study investigating the non-inferiority of efficacy and safety of a 2% miconazole nitrate shampoo in comparison with a 2% ketoconazole shampoo in the treatment of seborrhoeic dermatitis of the scalp. J Dermatol Treat. 2014;25:226–231.
   PubMed Web of Science ®Google Scholar
• Azimi H, Golforoushan F, Jaberian M, et al. Efficiency of terbinafine 1% cream in comparison with ketoconazole 2% cream and placebo in patients with facial seborrheic dermatitis. J Dermatol Treat. 2013. [Epub ahead of print]
   PubMedGoogle Scholar
• Okokon EO, Verbeek JH, Ruotsalainen JH, et al. Topical antifungals for seborrhoeic dermatitis. Cochrane Database Syst Rev. 2015;CD008138.
   PubMedGoogle Scholar
• Faergemann J. Seborrhoeic dermatitis and Pityrosporum orbiculare: treatment of seborrhoeic dermatitis of the scalp with miconazole-hydrocortisone (Daktacort), miconazole and hydrocortisone. Br J Dermatol. 1986;114:695–700.
   PubMed Web of Science ®Google Scholar
• Attarzadeh Y, Asilian A, Shahmoradi Z, et al. Comparing the efficacy of Emu oil with clotrimazole and hydrocortisone in the treatment of seborrheic dermatitis: a clinical trial. J Res Med Sci. 2013;18:477–481.
   PubMed Web of Science ®Google Scholar
• Goldust M, Rezaee E, Rouhani S. Double blind study of sertaconazole 2% cream vs. clotrimazole 1% cream in treatment of seborrheic dermatitis. J Dermatol Treat. 2013;59:25–29.
   Google Scholar
• Gupta AK, Bluhm R. Ciclopirox (Loprox) gel for superficial fungal infections. Skin Therapy Lett. 2004;9:4–5.
   Google Scholar
• Aly R, Katz HI, Kempers SE, et al. Ciclopirox gel for seborrheic dermatitis of the scalp. Int J Dermatol. 2003;42:19–22.
   PubMed Web of Science ®Google Scholar
• Ryder NS. Terbinafine: mode of action and properties of the squalene epoxidase inhibition. Br J Dermatol. 1992;126:2–7.
   PubMed Web of Science ®Google Scholar
• Rigopoulos D, Ioannides D, Kalogeromitros D, et al. Pimecrolimus cream 1% vs. betamethasone 17-valerate 0.1% cream in the treatment of seborrhoeic dermatitis. A randomized open-label clinical trial. Br J Dermatol. 2004;151:1071–1075.
   PubMed Web of Science ®Google Scholar
• Ortonne JP, Lacour JP, Vitetta A, et al. Comparative study of ketoconazole 2% foaming gel and betamethasone dipropionate 0.05% lotion in the treatment of seborrhoeic dermatitis in adults. Dermatology (Basel). 1992;184:275–280.
   PubMed Web of Science ®Google Scholar
• Balighi K, Ghodsi SZ, Daneshpazhooh M, et al. Hydrocortisone 1% cream and sertaconazole 2% cream to treat facial seborrheic dermatitis: a double-blind, randomized clinical trial. Int J Womens Dermatol. 2017;3:107–110.
   PubMedGoogle Scholar
• Goldust M, Rezaee E, Masoudnia S, et al. Clinical study of sertaconazole 2% cream vs. hydrocortisone 1% cream in the treatment of seborrheic dermatitis. Ann Parasitol. 2013;59:119–123.
   PubMedGoogle Scholar
• Youn HJ, Kim SY, Park M, et al. Efficacy and safety of cream containing climbazole/piroctone olamine for facial seborrheic dermatitis: a single-center, open-label split-face clinical study. Ann Dermatol. 2016;28:733–739.
   PubMed Web of Science ®Google Scholar
• Veraldi S, Menter A, Innocenti M. Treatment of mild to moderate seborrhoeic dermatitis with MAS064D (Sebclair), a novel topical medical device: results of a pilot, randomized, double-blind, controlled trial. J Eur Acad Dermatol Venerol. 2008;22:290–296.
   PubMed Web of Science ®Google Scholar
• Turlier V, Viode C, Durbise E, et al. Clinical and biochemical assessment of maintenance treatment in chronic recurrent seborrheic dermatitis: randomized controlled study. Dermatol Ther (Heidelb). 2014;4:43–59.
   PubMedGoogle Scholar
• Dall'oglio F, Tedeschi A, Fusto CM, et al. A novel cosmetic antifungal/anti-inflammatory topical gel for the treatment of mild to moderate seborrheic dermatitis of the face: a open-label trial utilizing clinical evaluation and erythemadirected digital photography. G Ital Dermatol Venereol. 2017;152:436–440.
   PubMed Web of Science ®Google Scholar
• Schmidt-Rose T, Braren S, Folster H, et al. Efficacy of a piroctone olamine/climbazol shampoo in comparison with a zinc pyrithione shampoo in subjects with moderate to severe dandruff. Int J Cosmet Sci. 2011;33:276–282.
   PubMed Web of Science ®Google Scholar
• Kim Y, Alpmann P, Blaum-Feder S, et al. Increased in vivo efficacy of lenalidomide by addition of piroctone olamine. In Vivo. 2011;25:99–103.
   Google Scholar
• Van den Bossche H, Willemsens G, Cools W, et al. In vitro and in vivo effects of the antimycotic drug ketoconazole on sterol synthesis. Antimicrob Agents Chemother. 1980;17:922–928.
   PubMed Web of Science ®Google Scholar
• Joly V, Bolard J, Yeni P. In vitro models for studying toxicity of antifungal agents. Antimicrob Agents Chemother. 1992;36:1799–1804.
   PubMed Web of Science ®Google Scholar
• Braga PC, Dal Sasso M, Fonti E, et al. Antioxidant activity of bisabolol: inhibitory effects on chemiluminescence of human neutrophil bursts and cell-free systems. Pharmacology. 2009;83:110–115.
   PubMed Web of Science ®Google Scholar
• Dall'Oglio F, Tedeschi A, Guardabasso V, et al. Evaluation of a topical anti-inflammatory/antifungal combination cream in mild-to-moderate facial seborrheic dermatitis: an intra-subject controlled trial examining treated vs. untreated skin utilizing clinical features and erythema-directed digital photography. J Clin Aesthet Dermatol. 2015;8:33–38.
   PubMedGoogle Scholar
• Bhatia N. Treating seborrheic dermatitis: review of mechanisms and therapeutic options. J Drugs Dermatol. 2013;42:796–798.
   Google Scholar
• Del Rosso JQ. Adult seborrheic dermatitis: a status report on practical topical management. J Clin Aesthet Dermatol. 2011;4:32–38.
   PubMedGoogle Scholar
• Kroes BH, Beukelman CJ, van den Berg AJ, et al. Inhibition of human complement by beta-glycyrrhetinic acid. Immunology. 1997;90:115–120.
   PubMed Web of Science ®Google Scholar
• Legrand D, Elass E, Carpentier M, et al. Lactoferrin: a modulator of immune and inflammatory responses. Cell Mol Life Sci. 2005;62:2549–2559.
   PubMed Web of Science ®Google Scholar
• Elewski B. An investigator-blind, randomized, 4-week, parallel-group, multicenter pilot study to compare the safety and efficacy of a nonsteroidal cream (Promiseb Topical Cream) and desonide cream 0.05% in the twice-daily treatment of mild to moderate seborrheic dermatitis of the face. Clin Dermatol. 2009;27:S48–S53.
   PubMed Web of Science ®Google Scholar
• Braza TJ, DiCarlo JB, Soon SL, et al. Tacrolimus 0.1% ointment for seborrhoeic dermatitis: an open-label pilot study. Br J Dermatol. 2003;148:1242–1244.
   PubMed Web of Science ®Google Scholar
• Goldust M, Rezaee E, Raghifar R, et al. Treatment of seborrheic dermatitis: the efficiency of sertaconazole 2% cream vs. tacrolimus 0.03% cream. Ann Parasitol. 2013;59:73–77.
   PubMedGoogle Scholar
• Kim TW, Mun JH, Jwa SW, et al. Proactive treatment of adult facial seborrhoeic dermatitis with 0.1% tacrolimus ointment: randomized, double-blind, vehicle-controlled, multi-centre trial. Acta Derm Venereol. 2013;93:557–561.
   PubMed Web of Science ®Google Scholar
• Meshkinpour A, Sun J, Weinstein G. An open pilot study using tacrolimus ointment in the treatment of seborrheic dermatitis. J Am Acad Dermatol. 2003;49:145–147.
   PubMed Web of Science ®Google Scholar
• Kim BS, Kim SH, Kim MB, et al. Treatment of facial seborrheic dermatitis with pimecrolimus cream 1%: an open-label clinical study in Korean patients. J Korean Med Sci. 2007;22:868–872.
   PubMed Web of Science ®Google Scholar
• Brownell I, Quan LT, Hsu S. Topical pimecrolimus in the treatment of seborrheic dermatitis. Dermatol Online J. 2003;9:13.
   PubMedGoogle Scholar
• Ozden MG, Tekin NS, Ilter N, et al. Topical pimecrolimus 1% cream for resistant seborrheic dermatitis of the face: an open-label study. Am J Clin Dermatol. 2010;11:51–54.
   PubMed Web of Science ®Google Scholar
• Warshaw EM, Wohlhuter RJ, Liu A, et al. Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis. J Am Acad Dermatol. 2007;57:257–264.
   PubMed Web of Science ®Google Scholar
• Cunha PR. Pimecrolimus cream 1% is effective in seborrhoeic dermatitis refractory to treatment with topical corticosteroids. Acta Derm Venereol. 2006;86:69–70.
   PubMed Web of Science ®Google Scholar
• Rallis E, Nasiopoulou A, Kouskoukis C, et al. Pimecrolimus cream 1% can be an effective treatment for seborrheic dermatitis of the face and trunk. Drugs Under Exp Clin Res. 2004;30:191–195.
   PubMedGoogle Scholar
• High WA, Pandya AG. Pilot trial of 1% pimecrolimus cream in the treatment of seborrheic dermatitis in African American adults with associated hypopigmentation. J Am Acad Dermatol. 2006;54:1083–1088.
   PubMed Web of Science ®Google Scholar
• de Moraes AP, de Arruda EA, Vitoriano MA, et al. An open-label efficacy pilot study with pimecrolimus cream 1% in adults with facial seborrhoeic dermatitis infected with HIV. J Eur Acad Dermatol Venerol. 2007;21:596–601.
   PubMed Web of Science ®Google Scholar
• Tatlican S, Eren C, Eskioglu F. Insight into pimecrolimus experience in seborrheic dermatitis: close follow-up with exact mean cure and remission times and side-effect profile. J Dermatol Treat. 2009;20:198–202.
   PubMed Web of Science ®Google Scholar
• Tatlican S, Eren C, Oktay B, et al. Experience with repetitive use of pimecrolimus: exploring the effective and safe use in the treatment of relapsing seborrheic dermatitis. J Dermatol Treat. 2010;21:83–85.
   PubMed Web of Science ®Google Scholar
• Firooz A, Solhpour A, Gorouhi F, et al. Pimecrolimus cream, 1%, vs hydrocortisone acetate cream, 1%, in the treatment of facial seborrheic dermatitis: a randomized, investigator-blind, clinical trial. Arch Dermatol. 2006;142:1066–1067.
   PubMedGoogle Scholar
• Koc E, Arca E, Kose O, et al. An open, randomized, prospective, comparative study of topical pimecrolimus 1% cream and topical ketoconazole 2% cream in the treatment of seborrheic dermatitis. J Dermatol Treat. 2009;20:4–9.
   PubMed Web of Science ®Google Scholar
• Cicek D, Kandi B, Bakar S, et al. Pimecrolimus 1% cream, methylprednisolone aceponate 0.1% cream and metronidazole 0.75% gel in the treatment of seborrhoeic dermatitis: a randomized clinical study. J Dermatol Treat. 2009;20:344–349.
   PubMed Web of Science ®Google Scholar
• Kim GK, Rosso JD. Topical pimecrolimus 1% cream in the treatment of seborrheic dermatitis. J Clin Aesthet Dermatol. 2013;6:29–35.
   PubMedGoogle Scholar
• Patel TS, Greer SC, Skinner RB Jr. Cancer concerns with topical immunomodulators in atopic dermatitis: overview of data and recommendations to clinicians. Am J Clin Dermatol. 2007;8:189–194.
   PubMed Web of Science ®Google Scholar
• Goldust M, Rezaee E, Raghifar R. Treatment of seborrheic dermatitis: comparison of sertaconazole 2% cream versus pimecrolimus 1% cream. Ir J Med Sci. 2013;182:703–706.
   PubMed Web of Science ®Google Scholar
• Ang-Tiu CU, Meghrajani CF, Maano CC. Pimecrolimus 1% cream for the treatment of seborrheic dermatitis: a systematic review of randomized controlled trials. Expert Rev Clin Pharmacol. 2012;5:91–97.
   PubMed Web of Science ®Google Scholar
• Miyachi Y, Imamura S, Niwa Y. Anti-oxidant action of metronidazole: a possible mechanism of action in rosacea. Br J Dermatol. 1986;114:231–234.
   PubMed Web of Science ®Google Scholar
• Grove DI, Mahmound AA, Warren KS. Suppression of cell-mediated immunity by metronidazole. Int Arch Allergy Appl Immunol. 1977;54:422–427.
   PubMedGoogle Scholar
• Parsad D, Pandhi R, Negi KS, et al. Topical metronidazole in seborrheic dermatitis-a double-blind study. Dermatology (Basel). 2001;202:35–37.
   PubMed Web of Science ®Google Scholar
• Koca R, Altinyazar HC, Esturk E. Is topical metronidazole effective in seborrheic dermatitis? A double-blind study. Int J Dermatol. 2003;42:632–635.
   PubMed Web of Science ®Google Scholar
• Siadat AH, Iraji F, Shahmoradi Z, et al. The efficacy of 1% metronidazole gel in facial seborrheic dermatitis: a double blind study. Indian J Dermatol Venereol Leprol. 2006;72:266–269.
   PubMedGoogle Scholar
• Garcia RL, Miller JD, Miller WN. Occlusive tar extract therapy for recalcitrant psoriasis and seborrheic dermatitis of the scalp. Cutis. 1978;22:90–91.
   PubMed Web of Science ®Google Scholar
• Seite S, Rougier A, Talarico S. Randomized study comparing the efficacy and tolerance of a lipohydroxy acid shampoo to a ciclopiroxolamine shampoo in the treatment of scalp seborrheic dermatitis. J Cosmet Dermatol. 2009;8:249–253.
   PubMed Web of Science ®Google Scholar
• Emtestam L, Svensson A, Rensfeldt K. Treatment of seborrhoeic dermatitis of the scalp with a topical solution of urea, lactic acid, and propylene glycol (K301): results of two double-blind, randomised, placebo-controlled studies. Mycoses. 2012;55:393–403.
   PubMed Web of Science ®Google Scholar
• Danby FW, Maddin WS, Margesson LJ, et al. A randomized, double-blind, placebo-controlled trial of ketoconazole 2% shampoo versus selenium sulfide 2.5% shampoo in the treatment of moderate to severe dandruff. J Am Acad Dermatol. 1993;29:1008–1012.
   PubMed Web of Science ®Google Scholar
• Hald M, Arendrup MC, Svejgaard EL, et al. Evidence-based Danish guidelines for the treatment of Malassezia-related skin diseases. Acta Derm Venereol. 2015;95:12–19.
   PubMed Web of Science ®Google Scholar
• Draelos ZD. The multifunctionality of 10% sodium sulfacetamide, 5% sulfur emollient foam in the treatment of inflammatory facial dermatoses. J Drugs Dermatol. 2010;9:234–236.
   PubMed Web of Science ®Google Scholar
• Johnson BA, Nunley JR. Treatment of seborrheic dermatitis. Am Fam Physician. 2000;61:2703–2710.
   PubMed Web of Science ®Google Scholar
• Cuelenaere C, De Bersaques J, Kint A. Use of topical lithium succinate in the treatment of seborrhoeic dermatitis. Dermatology (Basel). 1992;184:194–197.
   PubMed Web of Science ®Google Scholar
• Boyle J, Burton JL, Faergemann J. Use of topical lithium succinate for seborrhoeic dermatitis. Br Med J (Clin Res Ed). 1986;292:28.
   PubMedGoogle Scholar
• Efalith Multicenter Trial Group. A double-blind, placebo-controlled, multicenter trial of lithium succinate ointment in the treatment of seborrheic dermatitis. J Am Acad Dermatol. 1992;26:452–457.
   PubMed Web of Science ®Google Scholar
• Dreno B, Moyse D. Lithium gluconate in the treatment of seborrhoeic dermatitis: a multicenter, randomised, double-blind study versus placebo. Eur J Dermatol. 2002;12:549–552.
   PubMed Web of Science ®Google Scholar
• Dreno B, Chosidow O, Revuz J, et al. Lithium gluconate 8% vs ketoconazole 2% in the treatment of seborrhoeic dermatitis: a multicentre, randomized study. Br J Dermatol. 2003;148:1230–1236.
   PubMed Web of Science ®Google Scholar
• Dahl KB, Reymann F. Photochemotherapy in erythrodermic seborrhoic dermatitis. Arch Dermatol. 1977;113:1295–1296.
   PubMedGoogle Scholar
• Salo O, Lassus A, Juvakoski T. Behandlung der Dermatitis atopica und der Dermatitis seborrhoica mit selektiver UV-Photo-therapie und PUVA. Dermatol Monatsschr. 1983;169:371–375.
   PubMedGoogle Scholar
• Tegner E. Seborrhoeic dermatitis of the face induced by PUVA treatment. Acta Derm Venereol. 1983;63:335–339.
   PubMed Web of Science ®Google Scholar
• Weichenthal M, Schwarz T. Phototherapy: how does UV work? Photodermatol Photoimmunol Photomed. 2005;21:260–266.
   PubMed Web of Science ®Google Scholar
• Nickoloff BJ. Cracking the cytokine code in psoriasis. Nat Med. 2007;13:242–244.
   PubMed Web of Science ®Google Scholar
• van Weelden H, De La Faille HB, Young E, et al. A new development in UVB phototherapy of psoriasis. Br J Dermatol. 1988;119:11–19.
   PubMed Web of Science ®Google Scholar
• Honig B, Morison WL, Karp D. Photochemotherapy beyond psoriasis. J Am Acad Dermatol. 1994;31:775–790.
   PubMed Web of Science ®Google Scholar
• Herzinger T, Berneburg M, Ghoreschi K, et al. S1-Guidelines on UV phototherapy and photochemotherapy. J Dtsch Dermatol Ges. 2016;14:853–876.
   PubMed Web of Science ®Google Scholar
• Pirkhammer D, Seeber A, Honigsmann H, et al. Narrow-band ultraviolet B (ATL-01) phototherapy is an effective and safe treatment option for patients with severe seborrhoeic dermatitis. Br J Dermatol. 2000;143:964–968.
   PubMed Web of Science ®Google Scholar
• Benaim-Pinto C. Topical glycerin in seborrhoeic dermatitis. Lancet. 1972;2:1037–1038.
   PubMed Web of Science ®Google Scholar
• Bonnetblanc JM, Bernard P. Benzoyl peroxide in seborrheic dermatitis. Arch Dermatol. 1986;122:752.
   PubMedGoogle Scholar
• Bowe WP, Shalita AR. Effective over-the-counter acne treatments. Semin Cutan Med Surg. 2008;27:170–176.
   PubMed Web of Science ®Google Scholar
• Al-Waili NS. Therapeutic and prophylactic effects of crude honey on chronic seborrheic dermatitis and dandruff. Eur J Med Res. 2001;6:306–308.
   PubMed Web of Science ®Google Scholar
• Hashemi SA, Madani SA, Abediankenari S. The review on properties of aloe vera in healing of cutaneous wounds. Biomed Res Int. 2015;2015:714216.
   PubMedGoogle Scholar
• Rosca-Casian O, Parvu M, Vlase L, et al. Antifungal activity of Aloe vera leaves. Fitoterapia. 2007;78:219–222.
   PubMed Web of Science ®Google Scholar
• Comacchi C, Hercogova J. A single mud treatment induces normalization of stratum corneum hydration, transepidermal water loss, skin surface pH and sebum content in patients with seborrhoeic dermatitis. J Eur Acad Dermatol Venerol. 2004;18:372–374.
   PubMed Web of Science ®Google Scholar
• Tollesson A, Frithz A. Borage oil, an effective new treatment for infantile seborrhoeic dermatitis. Br J Dermatol. 1993;129:95.
   PubMed Web of Science ®Google Scholar
• Tollesson A, Frithz A, Stenlund K. Malassezia furfur in infantile seborrheic dermatitis. Pediatr Dermatol. 1997;14:423–425.
   PubMed Web of Science ®Google Scholar
• Pazyar N, Yaghoobi R, Bagherani N, et al. A review of applications of tea tree oil in dermatology. Int J Dermatol. 2013;52:784–790.
   PubMed Web of Science ®Google Scholar
• Satchell AC, Saurajen A, Bell C, et al. Treatment of dandruff with 5% tea tree oil shampoo. J Am Acad Dermatol. 2002;47:852–855.
   PubMed Web of Science ®Google Scholar
• Nenoff P, Haustein UF, Brandt W. Antifungal activity of the essential oil of Melaleuca alternifolia (tea tree oil) against pathogenic fungi in vitro. Skin Pharmacol Physiol. 1996;9:388–394.
   Google Scholar
• Diehl C, Ferrari A. Efficacy of topical 4% Quassia amara gel in facial seborrheic dermatitis:a randomized, double-blind, comparative study. J Clin Cosmet Dermatol. 2013;12:312–315.
   Google Scholar
• Herrera-Arellano A, Jimenez-Ferrer E, Vega-Pimentel AM, et al. Clinical and mycological evaluation of therapeutic effectiveness of Solanum chrysotrichum standardized extract on patients with Pityriasis capitis (dandruff). A double blind and randomized clinical trial controlled with ketoconazole. Planta Med. 2004;70:483–488.
   PubMed Web of Science ®Google Scholar
• Caspeta L, Nieto I, Zamilpa A, et al. Solanum chrysotrichum hairy root cultures: characterization, scale-up and production of five antifungal saponins for human use. Planta Med. 2005;71:1084–1087.
   PubMed Web of Science ®Google Scholar
• Gupte TE, Gaikwad UV, Naik SR. Experimental studies (in vitro) on polyene macrolide antibiotics with special reference to hamycin against Malassezia ovale. Comp Immunol Microbiol Infect Dis. 1999;22:93–102.
   PubMed Web of Science ®Google Scholar
• Zisova LG. Fluconazole and its place in the treatment of seborrheic dermatitis–new therapeutic possibilities. Folia Med (Plovdiv). 2006;48:39–45.
   PubMedGoogle Scholar
• Vena GA, Micali G, Santoianni P, et al. Oral terbinafine in the treatment of multi-site seborrhoic dermatitis: a multicenter, double-blind placebo-controlled study. Int J Immunopathol Pharmacol. 2005;18:745–753.
   PubMed Web of Science ®Google Scholar
• Cassano N, Amoruso A, Loconsole F, et al. Oral terbinafine for the treatment of seborrheic dermatitis in adults. Int J Dermatol. 2002;41:821–822.
   PubMed Web of Science ®Google Scholar
• Scaparro E, Quadri G, Virno G, et al. Evaluation of the efficacy and tolerability of oral terbinafine (Daskil) in patients with seborrhoeic dermatitis. A multicentre, randomized, investigator-blinded, placebo-controlled trial. Br J Dermatol. 2001;144:854–857.
   PubMed Web of Science ®Google Scholar
• Zisova LG. Treatment of Malassezia species associated seborrheic blepharitis with fluconazole. Folia Med (Plovdiv). 2009;51:57–59.
   PubMedGoogle Scholar
• Comert A, Bekiroglu N, Gurbuz O, et al. Efficacy of oral fluconazole in the treatment of seborrheic dermatitis: a placebo-controlled study. Am J Clin Dermatol. 2007;8:235–238.
   PubMed Web of Science ®Google Scholar
• Mesquita Kde C, Igreja AC, Costa IM. Seborrheic dermatitis: is there room for systemic corticosteroids? An Bras Dermatol. 2012;87:507.
   PubMed Web of Science ®Google Scholar
• de Souza Leao Kamamoto C, Sanudo A, Hassun KM, et al. Low-dose oral isotretinoin for moderate to severe seborrhea and seborrheic dermatitis: a randomized comparative trial. Int J Dermatol. 2017;56:80–85.
   PubMed Web of Science ®Google Scholar
• Ghodsi SZ, Abbas Z, Abedeni R. Efficacy of oral itraconazole in the treatment and relapse prevention of moderate to severe seborrheic dermatitis: a randomized, placebo-controlled trial. Am J Clin Dermatol. 2015;16:431–437.
   PubMed Web of Science ®Google Scholar
• Das J, Majumdar M, Chakraborty U, et al. Oral itraconazole for the treatment of severe seborrhoeic dermatitis. Indian J Dermatol. 2011;56:515–516.
   PubMedGoogle Scholar
• Shemer A, Kaplan B, Nathansohn N, et al. Treatment of moderate to severe facial seborrheic dermatitis with itraconazole: an open non-comparative study. Isr Med Assoc J. 2008;10:417–418.
   PubMed Web of Science ®Google Scholar
• Jensen JC. Clinical pharmacokinetics of terbinafine (Lamisil). Clin Exp Dermatol. 1989;14:110–113.
   PubMed Web of Science ®Google Scholar
• Petersen EA, Alling DW, Kirkpatrick CH. Treatment of chronic mucocutaneous candidiasis with ketoconazole: a controlled clinical trial. Ann Intern Med. 1980;93:791–795.
   PubMed Web of Science ®Google Scholar
• Ford GP, Farr PM, Ive FA, et al. The response of seborrhoeic dermatitis to ketoconazole. Br J Dermatol. 1984;111:603–607.
   PubMed Web of Science ®Google Scholar
• Odds F, Ausma J, Van Gerven F, et al. In vitro and in vivo activities of the novel azole antifungal agent r126638. Antimicrob Agents Chemother. 2004;48:388–391.
   PubMed Web of Science ®Google Scholar
• Vanden Bossche H, Ausma J, Bohets H, et al. The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004;48:3272–3278.
   PubMed Web of Science ®Google Scholar
• Pierard GE, Ausma J, Henry F, et al. A pilot study on seborrheic dermatitis using pramiconazole as a potent oral anti-Malassezia agent. Dermatology (Basel). 2007;214:162–169.
   PubMed Web of Science ®Google Scholar
• Zouboulis CC. Isotretinoin revisited: pluripotent effects on human sebaceous gland cells. J Invest Dermatol. 2006;126:2154–2156.
   PubMed Web of Science ®Google Scholar
• Nelson AM, Zhao W, Gilliland KL, et al. Isotretinoin temporally regulates distinct sets of genes in patient skin. J Invest Dermatol. 2009;129:1038–1042.
   PubMed Web of Science ®Google Scholar
• King K, Jones DH, Daltrey DC, et al. A double-blind study of the effects of 13-cis-retinoic acid on acne, sebum excretion rate and microbial population. Br J Dermatol. 1982;107:583–590.
   PubMed Web of Science ®Google Scholar
• Rademaker M. Low-dose isotretinoin for seborrhoeic dermatitis. J Cutan Med Surg. 2017;21:170–171.
   PubMed Web of Science ®Google Scholar
• Smith SA, Baker AE, Williams JH. Effective treatment of seborrheic dermatitis using a low dose, oral homeopathic medication consisting of potassium bromide, sodium bromide, nickel sulfate, and sodium chloride in a double-blind, placebo-controlled study. Alternat Med Rev: J Clin Ther. 2002;7:59–67.
   PubMedGoogle Scholar
• Brenner S, Horwitz C. Possible nutrient mediators in psoriasis and seborrheic dermatitis. II. Nutrient mediators: essential fatty acids; vitamins A, E and D; vitamins B1, B2, B6, niacin and biotin; vitamin C selenium; zinc; iron. World Rev Nutr Diet. 1988;55:165–182.
   PubMedGoogle Scholar
• Schwartz JR, Marsh RG, Draelos ZD. Zinc and skin health: overview of physiology and pharmacology. Dermatol Surg: off Publ Am Soc Dermatol Surg. 2005;31:837–847. discussion 47.
   PubMed Web of Science ®Google Scholar
• Nisenson A, Barness LA. Treatment of seborrheic dermatitis with biotin and vitamin B complex. J Pediatr. 1972;81:630–631.
   PubMed Web of Science ®Google Scholar
• Messaritakis J, Kattamis C, Karabula C, et al. Generalized seborrhoeic dermatitis. Clinical and therapeutic data of 25 patients. Arch Dis Child. 1975;50:871–874.
   PubMed Web of Science ®Google Scholar
• Keipert JA. Oral use of biotin in seborrhoeic dermatitis of infancy: a controlled trial. Med J Aust. 1976;1:584–585.
   PubMed Web of Science ®Google Scholar
• Fabbrocini G, Cantelli M, Monfrecola G. Topical nicotinamide for seborrheic dermatitis: an open randomized study. J Dermatol Treat. 2014;25:241–245.
   PubMed Web of Science ®Google Scholar
• Nakayama J. Four cases of sebopsoriasis or seborrheic dermatitis of the face and scalp successfully treated with 1a-24 (R)-dihydroxycholecalciferol (tacalcitol) cream. Eur J Dermatol. 2000;10:528–532.
   PubMed Web of Science ®Google Scholar
• Pierard GE, Pierard-Franchimont C. Effect of a topical erythromycin-zinc formulation on sebum delivery. Evaluation by combined photometric-multi-step samplings with Sebutape. Clin Exp Dermatol. 1993;18:410–413.
   PubMed Web of Science ®Google Scholar